Exelixis Inc
(NAS:EXEL)
$
35.91
0.06 (0.17%)
Market Cap: 10.26 Bil
Enterprise Value: 9.24 Bil
PE Ratio: 23.02
PB Ratio: 4.51
GF Score: 91/100 
Exelixis Inc at UBS Global Healthcare Conference Transcript
May 21, 2019 / 02:00PM GMT
Release Date Price:
$20.43
(+4.18%)
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
Hello. Welcome to our next session with Exelixis. I'm happy to have with me here Michael Morrissey, the CEO. My name is Navin Jacob. I'm the senior analyst covering large cap pharmaceuticals and smid cap biotech. Thank you for joining us, Michael.
Michael M. Morrissey
Exelixis, Inc. - CEO, President & Director
Yes. Great to be here.
Questions & Answers
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic
So maybe we could start with cabo in RCC. Recently, KEYTRUDA plus lenalido was launched. How should we think about that launch? Are you seeing any impact so far?
Michael M. Morrissey
Exelixis, Inc. - CEO, President & Director
Yes. Well, first, thanks for the invite. It's great to be here today. I'll be making forward-looking
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers